Joseph Papaparaskevas, MD, PhD, Curriculum Vitae

**Name:** Joseph Papaparaskevas

**Date of Birth:** October 17, 1965

**Gender:** Male

**Place of Birth:** Thessaloniki, Greece

**Family status:** Married, two children

**Home address:** Nikolaou Plastira 19, 151 21, Pevki, Athens, Greece (tel. +30-210-6128066)

**Business address:** Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Mikras Asias 75, 115 27, Goudi, Athens, Greece (Tel +30-210-7462142, Fax +30-210-7462143, e-mail: [ipapapar@med.uoa.gr](mailto:ipapapar@med.uoa.gr))

**Medical Diploma:** 1991; Medical School, University of Ioannina, Ioannina, Greece.

**Military Service:** 1991 – 1992, 216th MASH (Mobile Army Surgical Hospital), Alexandroupoli, Greece.

**Rural Service:** 1992 – 1993, Parakalamos, Ioannina, Greece.

**Residency in Medical Biopathology:** 1993 –1998; "Laikon" General Hospital, Athens, Greece

**Diplomate of the Greek Board of Medical Biopathology:** July 1st 1999.

**Ph.D. Degree:** 1996 – 2000; Department of Epidemiology, Medical School, National and Kapodistrian University of Athens, Greece (Thesis title: Molecular epidemiology of nosocomial infections caused by multiresistant *Enterococcus* spp. isolates)

**Postdoc Research Position**: 2000-2002; Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Greece

**Employment**

1. April 2017 – Today: Associate Professor, Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Greece. Scientific Supervisor of the Bacteriology - Molecular Diagnostic Unit and the Biosafety Level III Containment Laboratory. Biosafety and Biosecurity Officer of the Department of Microbiology.
2. June 2011 – April 2017: Assistant Professor, Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Greece. Scientific Supervisor of the Bacteriology - Molecular Diagnostic Unit and the Biosafety Level III Containment Laboratory. Biosafety and Biosecurity Officer of the Department of Microbiology.
3. February 2004 – June 2011: Lecturer, Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Greece.
4. October 2002 – February 2004:Consultant Clinical Microbiologist, National Health System (NHS), Department of Microbiology, “Laikon” General Hospital, Athens, Greece.

**Main Research Interests**

1. Epidemiology of bacterial infections.
2. Mechanisms of bacterial resistance.
3. Anaerobic bacteriology.
4. Molecular diagnosis of bacterial infections.
5. Highly pathogenic bacteria, diagnosis and susceptibility testing.
6. Bacteriological agents of deliberate release, detection and prevention.
7. Biosafety and Biosecurity in the Microbiology Laboratory.

**International activity, membership in scientific societies, scientific journals editorial boards**

* Hellenic Society for Microbiology, member (since 1995).
* Study Group for Quality Assurance and Biosafety, Hellenic Society for Microbiology, member (2011-2013).
* European Society of Clinical Microbiology and Infectious Diseases (ESCMID), member (since 1996).
* ESCMID Study Group for Anaerobic Infections (ESGAI), member of the Executive Committee (2012-2016).
* American Society for Microbiology (ASM), member (since 2005).
* Acta Microbiologica Hellenica (Journal of the Hellenic Society for Microbiology), member of the Scientific Committee (2009-2011), Editor (2011-present)
* Anaerobe Journal, Elsevier Publishing, member of the Editorial Board (2012-present)

**Personal Web pages and other web-based resources**

1. University of Athens web pages: <http://school.med.uoa.gr/melhdep/bio/527-ipapapar-med-uoa-gr.html> (in Greek), <http://school.med.uoa.gr/en/faculty/faculty-details/528-2107462142.html> (in English) and <http://scholar.uoa.gr/ipapapar> (in English)
2. Department of Microbiology web pages: <http://www.med.uoa.gr/microbiology/Papaparaskevas.html> (in Greek) and <http://www.med.uoa.gr/microbiology/files/Download/molecular_diagnosis.pdf> (in Greek)
3. LinkedIn web page: <https://www.linkedin.com/profile/view?id=AAIAAAW1L3gBYkjJF38VgjD7ZJ1sUFO8xHOW7mA&trk=nav_responsive_tab_profile>
4. Research Gate web page: <https://www.researchgate.net/profile/Joseph_Papaparaskevas>
5. Kudos Research web page: <https://www.growkudos.com/profiles/30917>
6. ORCID number: 0000-0001-9188-243X (<http://www.orcid.org/0000-0001-9188-243X&authorId=6603462581&origin=AuthorProfile&orcId=0000-0001-9188-243X&category=orcidLink>)
7. Scopus author ID: 6603462581 (<http://www.scopus.com/authid/detail.url?authorId=6603462581>)

**List of international publications as an author (N=44)**

1. Postanginal sepsis syndrome with metastatic lung abscess in a young man. Avlami A, Schina M, Tzivra M, Stefanou I, **Papaparaskevas J, S**akellaropoulos N. *Anaerobe*, 1997;3:149-151 (doi: 10.1006/anae.1997.0092).
2. The first clinical isolate of *Enterococcus faecium* with the VanB phenotype in a teaching hospital in Greece. **Papaparaskevas J**, Stefanou I, Vatopoulos A, Thomopoulos G, Avlamis A. *Clinical Microbiology and Infection*, 1999;5:763-765.
3. Diversity among high-level aminoglycoside resistant enterococci. **Papaparaskevas J**, Vatopoulos A, Tassios PT, Avlamis A, Legakis NJ, Kalapothaki V*. Journal of Antimicrobial Chemotherapy*, 2000;45: 277-283 (doi: 0.1093/jac/45.3.277).
4. Rapid urease test is less sensitive than histology in diagnosing *Helicobacter pylori* infection in patients with non-variceal gastrointestinal bleeding. Archimandritis A, Tzivras M, Sougioultzis S, **Papaparaskevas J**, Apostolopoulos P, Avlami A, Davaris PS. *Journal of Gastroenterology and Hepatology* 2000;15:369-373 (doi: 10.1046/j.1440-1746.2000.02171.x).
5. First report of ampicillin and glycopeptide antibiotics resistant *Enterococcus faecium* VanA bacteraemia in Greece. Kouppari G, Papadaki H, Legakis NJ, Arida C, Sakellariou J, **Papaparaskevas J.** *International Journal of Antimicrobial Agents*, 2000;16:254-256 (doi: 10.1016/S0924-8579(00)00228-4).
6. Epidemiology of multiresistant *Enterococcus avium* isolates in a Greek tertiary care hospital. **Papaparaskevas J**, Tassios PT, Kalapothaki V, Avlami A, Legakis NJ, Vatopoulos AC. *International Journal of Antimicrobial Agents* 2002;20:432-437 (doi: 10.1016/S0924-8579(02)00238-8).
7. Predominance of two M-types among erythromycin-resistant Group A Streptococci from Greek children. Zachariadou L, **Papaparaskevas J**, Paraskakis I, Efstratiou A, Pangalis A, Legakis NJ, Tassios PT. *Clinical Microbiology and Infection* 2003;9:310-14 (doi: 10.1046/j.1469-0691.2003.00493.x).
8. Changes in the epidemiology of methicillin-resistant *Staphylococcus aureus* in a Greek tertiary care hospital, over an eight year period. Pantazatou A, **Papaparaskevas J**, Stefanou I, Papanicolas J, Demertzi E, Avlamis A. *International Journal of Antimicrobial Agents* 2003;21:542-546 (doi: 10.1016/S0924-8579(03)00055-4).
9. A common clone of erythromycin-resistant *Streptococcus pneumoniae* in Greece and the UK. Fotopoulou N, Tassios PT, Beste DV, Ioannidou S, Efstratiou A, Lawrence ER, **Papaparaskevas J**, Roberts RC, Legakis NJ. *Clinical Microbiology and Infection* 2003;9: 924-929 (doi: 10.1046/j.1469-0691.2003.00689.x).
10. Prevalence and characterization of the mechanisms of macrolide, lincosamide and streptogramin resistance in viridans group streptococci. Ioannidou S, **Papaparaskevas J**, Tassios PT, Foustoukou M, Legakis NJ, Vatopoulos AC. *International Journal of Antimicrobial Agents*;2003;22:626-629 (doi: 10.1016/j.ijantimicag.2003.05.001).
11. Ruling out *Bacillus anthracis*; evaluation of methodology. **Papaparaskevas J**, Houhoula D, Papadimitriou M, G. Saroglou, N.J. Legakis and L. Zerva. *Emerging Infectious Diseases*, 2004;10:732-735 (doi: 10.1007/s12024-014-9578-z).
12. Dissemination of vancomycin-resistant enterococci among haemodialysis patients in Athens, Greece. Kalocheretis P, Baimakou E, Zerbala S, **Papaparaskevas J**, Makriniotou I, Tassios PT, Iatrou C, Kouskouni E, Zerva L. *Journal of Antimicrobial Chemotherapy*,2004;54:1031-1034 (doi: 10.1093/jac/dkh450).
13. Multicentre survey of the *in-vitro* activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece. **Papaparaskevas J,** Pantazatou A, Katsandri A, Legakis NJ, the “Hellenic Study Group for Gram-Negative Anaerobic Bacteria”, Avlamis A. *Clinical Microbiology and Infection*, 2005;11:820-824 (doi: 10.1111/j.1469-0691.2005.01233.x).
14. *In vitro* activities of tigecycline against recently isolated Gram-negative anaerobic bacteria in Greece, including metronidazole resistant strains. Katsandri A, Avlamis A, Pantazatou A, Petrikkos GL, Legakis NJ, “The Hellenic Study Group for Gram-Negative Anaerobic Bacteria”, **Papaparaskevas J**. *Diagnostic Microbiology and Infectious Diseases,* 2006;55:231-236 (doi: 10.1016/j.diagmicrobio.2006.01.022).
15. Septic arthritis due to *Roseomonas mucosa* in a rheumatoid arthritis patient receiving infliximab therapy. Sipsas NV, **Papaparaskevas J**, Stefanou I, Kalatzis K, Vlachoyiannopoulos P, Avlamis A. *Diagnostic Microbiology and Infectious Diseases,* 2006;55:343-345 (doi: 10.1016/j.diagmicrobio.2006.01.028).
16. Dissemination of *nim*-class genes, encoding for nitroimidazole resistance, among different species of Gram-negative anaerobic bacteria, isolated in Athens, Greece. Katsandri A, Avlamis A, Pantazatou A, Houhoula D, **Papaparaskevas J**. *Journal of Antimicrobial Chemotherapy,* 2006;58:705-706 (doi: 10.1093/jac/dkl285).
17. Two cases of infections due to multi-drug resistant *Bacteroides fragilis* group strains. A. Katsandri, **J. Papaparaskevas,** A. Pantazatou, G.L. Petrikkos, G. Thomopoulos, D.P. Houhoula, and A. Avlamis. *Journal of Clinical Microbiology,* 2006;44:3465-67
18. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among *Klebsiella pneumoniae* and *Escherichia coli* clinical isolates following a restriction policy in a Greek tertiary care hospital. Petrikkos GL, Markogiannakis A, **Papaparaskevas J**, Daikos GL, Stefanakos G, Zissis NP, Avlamis A. *International Journal of Antimicrobial Agents,* 2007;29:34-38 (doi: 10.1016/j.ijantimicag.2006.08.042).

Erratum in: *International Journal of Antimicrobial Agents* 2007;30:287

1. Differences in the evolution of imipenem susceptibility among *Klebsiella pneumoniae* and *Escherichia coli* isolates, during a six-year period, in a tertiary care hospital. **Papaparaskevas J,** Pantazatou A, Stefanou I, Mela V, Galatidis N, Avlamis A. *International Journal of Antimicrobial Agents,* 2007;29:197-200 (doi: 10.1016/j.ijantimicag.2006.09.010).
2. Moxifloxacin resistance is prevalent among *Bacteroides* and *Prevotella* species in Greece. **Papaparaskevas J**, Pantazatou A, Katsandri A, Houhoula DP, Legakis NJ, Tsakris A, Avlamis A. *Journal of Antimicrobial Chemotherapy,* 2008;62:134-141 (doi: 10.1093/jac/dkn134).
3. Risk factors for coexistence of fluoroquinolone resistance and ESBL production among *Enterobacteriaceae* in a Greek university hospital. Katsandri A, Avlamis A, Vasilakopoulou A, Mela V, Kosmidis C, **Papaparaskevas J**, Petrikkos GL. *Journal of Chemotherapy,* 2008;20:452-457 (doi: 10.1179/joc.2008.20.4.452).
4. Prevalence of *emm*-types 1 and 12 from invasive *Streptococcus pyogenes* disease in Greece – results of enhanced surveillance. Stathi A, **Papaparaskevas J**, Zachariadou L, Pangalis A, Legakis NJ, Tseleni-Kotsovili A, the Hellenic Strep-EURO Study Group, Tassios PT. *Clinical Microbiology and Infection*, 2008;14:808-812 (doi: 10.1111/j.1469-0691.2008.02032.x).
5. Comparison of penile skin swab with intra-urethral swab and first void urine for PCR-based diagnosis of *Chlamydia trachomatis* urethritis in male patients. Pittaras TE, **Papaparaskevas J**, Houhoula DP, Legakis NJ, Frangouli E, Katsambas A, Tsakris A, Papadogeorgakis H. *Sexually Transmitted Diseases,* 2008;35:999-1001 (doi: 10.1097/OLQ.0b013e318182a586).
6. Molecular-beacon-based Real-Time PCR for detection and quantification of *Mycobacterium tuberculosis* DNA in clinical samples. **Papaparaskevas J**, Houhoula DP, Siatelis A, Tsakris A. *Journal of Clinical Microbiology,* 2008;46;3177-3178 (doi: 10.1128/JCM.00903-08).
7. Infant penile tuberculosis following circumcision. Papaevangelou V, Vintila A, **Papaparaskevas J**, Kanavaki S, Garoufi A, Tsoukatou T, Tsolia M. *Journal of Infection,* 2009;58:83-85 (doi: 10.1016/j.jinf.2008.11.011).
8. Colonization with multiple *Staphylococcus aureus* strains among patients in European Intensive Care Units. Bloemendaal ALA, Fluit AC, Jansen WTM, Vriens MR, Ferry T, Amorim JM, Pascual A, Stefani S, **Papaparaskevas J**, Borel-Rinkes IHM, Verhoef J. *Infection Control and Hospital Epidemiology,* 2009;30:918-920 (doi: 10.1086/605640).
9. *In vitro* activity of tigecycline against 2,423 clinical isolates and comparison of the available interpretation breakpoints. **Papaparaskevas J**, Tzouvelekis LS, Tsakris A, Pittaras TE, Legakis NJ, The Hellenic Tigecycline Study Group. *Diagnostic Microbiology and Infectious Diseases,* 2010;66:187-194 (doi: 10.1016/j.diagmicrobio.2009.09.012).
10. *Chlamydia trachomatis* serovar distribution and *Neisseria gonorrhoeae* coinfection in male patients with urethritis in Greece. Papadogeorgakis H, Pittaras TE, **Papaparaskevas J**, Pitiriga V, Katsambas A, Tsakris A. *Journal of Clinical Microbiology,* 2010:48;2231-2234 (doi: 10.1128/JCM.00586-10).
11. Detection of Bacillus Galmette-Guerin DNA in urine and blood specimens after intravesical immunotherapy for bladder carcinoma. Siatelis A, Houhoula DP, **Papaparaskevas J**, Delakas D, Tsakris A. *Journal of Clinical Microbiology,* 2011:49:1206-1208 (doi: 10.1128/JCM.01595-10).
12. Epidemiological characteristics of infections caused by *Bacteroides*, *Prevotella* and *Fusobacterium* species: a prospective observational study. **Papaparaskevas J**, Katsandri A, Pantazatou A, Stefanou I, Avlamis A, Legakis NJ, Tsakris A. *Anaerobe*, 2011;17:113-117 (doi: 10.1016/j.anaerobe.2011.05.013).
13. High level of heterogeneity among *Listeria monocytogenes* isolates from clinical and food origin specimens in Greece. Houhoula D, Pirasmaki D, Konteles S, Kizis D, Koussissis S, Bratacos M, Poggas N, Charvalos E, Tsakris A, **Papaparaskevas J**. *Foodborne Pathogens and Disease,* 2012;9:848-852 (doi:10.1089/fpd.2012.1187).
14. Cutaneous infection caused by *Bacillus anthracis* in Larissa, Thessaly, Central Greece, July 2012. Stefos A, Gatselis N, Goudelas A, Mpakarosi M, **Papaparaskevas J**, Dalekos G, Petinaki E. *Euro Surveillance*, 2012;17:32 (doi:pii:20245).
15. Incidence and risk factors for central vascular catheter-related bloodstream infections in a tertiary care hospital. Tarpatzi A, Avlamis A, **Papaparaskevas J**, Daikos GL, Stefanou I, Katsandri A, Vasilakopoulou A, Chatzigeorgiou KS, Petrikkos GL. *New Microbiolοgica*, 2012;35:429-437.
16. Antimicrobial efficacy of denture adhesives on some oral malodor-related microbes. Polyzois G, Stefaniotis T, **Papaparaskevas J**, Donta C. *Odontology,* 2013;101:103-107 (doi: 10.1007/s10266-011-0048-8).
17. Comparative evaluation of conventional and real-time PCR assays for detecting *Bacteroides fragilis* in clinical samples. **Papaparaskevas J**, Mela V, Houhoula DP, Pantazatou A, Petrikkos GL, Tsakris A. *Journal of Clinical Microbiology*, 2013;51:1593-1595 (doi: 10.1128/JCM.00449-13).
18. Granulomatous infection of the hand and wrist due to *Azospirillum* spp. Serelis J, **Papaparaskevas J**, Stathi A, Sawides AL, Karagouni AD, Tsakris A, Pangalis A. *Diagnostic Microbiology and Infectious Diseases*, 2013;76:513-515 (doi: 10.1016/j.diagmicrobio.2013.04.010).
19. Differences in the epidemiology between paediatric and adult invasive *Streptococcus pyogenes* infections. Zachariadou L, Stathi A, Tassios PT, Pangalis A, Legakis NJ, the Hellenic Strep-Euro Study Group. **Papaparaskevas J**. *Epidemiology and Infection* 2014;142:512-519 (doi: 10.1017/S0950268813001386).
20. Pitted keratolysis in an adolescent, diagnosed using conventional and molecular microbiology and successfully treated with fusidic acid. **Papaparaskevas J**, Stathi A, Alexandrou-Athanassoulis H, Charisiadou A, Petropoulou N, Tsakris A, Valari M. *European Journal of Dermatology*, 2014;24:499-500 (doi: 10.1684/ejd.2014.2376).
21. Detection of bacteria bearing resistant biofilm forms, by using the universal and specific PCR is still unhelpful in the diagnosis of periprosthetic joint infections. Zegaer ΒΗ, Ioannidis A, Babis GC, Ioannidou V, Kossyvakis A, Bersimis S, **Papaparaskevas J**, Petinaki E, Pliatsika P, Chatzipanagiotou S. *Frontiers in Medicine,* 2014;16:30 (doi: 10.3389/fmed.2014.00030).
22. A prospective study on bacterial and atypical etiology of acute exacerbation in chronic obstructive pulmonary disease. Nakou A, **Papaparaskevas J**, Diamantea F, Skarmoutsou N, Polychronopoulos V, Tsakris A. *Future Microbiology*, 2014;9:1251-60 (doi: 10.2217/fmb.14.90).
23. MLST typing of antimicrobial-resistant *Propionibacterium acnes* isolates from patients with moderate to severe acne vulgaris. Giannopoulos L, **Papaparaskevas J**, Refene E, Daikos G, Stavrianeas N, Tsakris A. *Anaerobe* 2015;31:50-54 (doi: 10.1016/j.anaerobe.2014.10.007).
24. Bronchiectasis exacerbations: The role of atypical bacteria, respiratory syncytial virus and pulmonary function tests. Metaxas EI, Balis E, **Papaparaskevas J**, Spanakis N, Tatsis G, Tsakris A. *Canadian Respiratory Journal*, 2015;22:163-166 (doi: .
25. 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan for monitoring the therapeutic response in experimental *Staphylococcus aureus* foreign-body osteomyelitis. Chatziioannou S, Papamichos O, Gamaletsou MN, Georgakopoulos A, Kostomitsopoulos NG, Tseleni-Balafouta S, **Papaparaskevas J**, Walsh TJ, Pneumaticos SG, Sipsas NV. *Journal of Orthopedic Surgery and Research*, 2015;10:132 (doi: 10.1186/s13018-015-0274-9).
26. Pneumonia and pleural empyema due to a mixed *Lactobacillus* spp. infection as a possible early esophageal carcinoma signature. Chaini E, Chainis ND, Ioannidis A, Magana M, Nikolaou C, **Papaparaskevas J**, Liakata MV, Katopodis P, Papastavrou L, Tegos GP, Chatzipanagiotou J. *Frontiers in Medicine*, 2016;3:42 doi: (10.3389/fmed.2016.00042).

**List of international publications as a Study Group member (N=12)**

1. Serotypes and antimicrobial susceptibilities of 1033 pneumococci isolated from children in Greece during 2001-2004. Paraskakis I, Kafetzis DA, Chrisakis A, Papavasilliou H, Kirikou H, Pangalis A, Tzouvelekis LS, Athanasiou T, Legakis NJ, and the National Surveillance Network for Pneumococcal Resistance**.** *Clinical Microbiology and Infection*, 2006;12:490-493 (doi: 10.1111/j.1469-0691.2006.01383.x).
2. International quality assurance study for characterization of *Streptococcus pyogenes*. Neal S, Beall B, Ekelund K, Henriques-Normark B, Jasir A, Johnson D, Kaplan E, Lovgren M, Reinert RR, Members of the Strep-EURO Study Group and International Streptococcus Reference Laboratories, and Efstratiou A**.** *Journal of**Clinical Microbiology*, 2007;45:1175-1179 (doi: 10.1128/JCM.02146-06).
3. Epidemiology of severe *Streptococcus pyogenes* disease in Europe. Lamagni TL, Darenberg J, Luca-Harari B, Siljander T, Efstratiou A, Henriques-Normark B, Vuopio-Varkila J, Bouvet A, Creti R, Ekelund K, Koliou M, Reinert RR, Stathi A, Strakova L, Ungureanu V, Schalen C, the Strep-EURO Study Group, and Jasir A**.** *Journal of**Clinical Microbiology*, 2008;46:2359-2367 (doi: 10.1128/JCM.00422-08).
4. Clinical and microbiological characteristics of severe *Streptococcus pyogenes* disease in Europe. Luca-Harari B, Darenberg J, Neal S, Siljander T, Strakova L, Tanna A, Creti R, Ekelund K, Koliou M, Tassios PT, van der Linden M, Straut M, Vuopio-Varkila J, Bouvet A, Efstratiou A, Schalen C, Henriques-Normark B, the Strep-EURO Study Group, and Jasir A**.** *Journal of**Clinical Microbiology*, 2009;47:1155-1165 (doi: 10.1128/JCM.02155-08).
5. Species identification of clinical isolates of Bacteroides by matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry. Nagy E, Maier T, Urban E, Terhes G, Kostrzewa M, the ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria**.** *Clinical Microbiology and Infection*, 2009;15:796-802 (doi: 10.1111/j.1469-0691.2009.02788.x).
6. Antimicrobial susceptibility of *Bacteroides fragilis* group isolates in Europe: 20 years of experience. E. Nagy, E. Urban, Carl Erik Nord, the ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. *Clinical Microbiology and Infection*, 2011;17:371-379 (doi: 10.1111/j.1469-0691.2010.03256.x).
7. Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study. Rossolini GM, Dryden MS, Kozlov RS, Quintana A, Flamm RK, Läuffer JM, Lee E, Morrissey I, the CLASS study group. *Journal of Antimicrobial Chemotherapy*, 2011;66:151–159 (doi: 10.1093/jac/dkq397).
8. Comparative activity of carbapenem testing: the COMPACT study. Nordmann P, Picazo JJ, Mutters R, Korten V, Quintana A, Laeuffer JM, Hian Seak JC, Flamm RK, Morrissey I, the COMPACT study group.*Journal of Antimicrobial Chemotherapy*, 2011;66:1070-1078 (doi: 10.1093/jac/dkr056).
9. Molecular analysis of the carbapenem and metronidazole resistance mechanisms of *Bacteroides* strains reported in a Europe-wide antibiotic resistance survey. Sóki J, Eitel Z, Urbán E, Nagy E, ESCMID Study Group on Anaerobic Infections.*International Journal of Antimicrobial Agents*, 2013;41:122-125 (doi: 10.1016/j.ijantimicag.2012.10.001).
10. The prevalence of antibiotic resistance genes in *Bacteroides fragilis* group strains isolated in different European countries. Eitel Z, Sóki J, Urbán E, Nagy E, ESCMID Study Group on Anaerobic Infection.*Anaerobe*, 2013;21:43-49 (doi: 10.1016/j.anaerobe.2013.03.001).
11. The association between colonization with Carbapenemase-producing Enterobacteriaceae and overall ICU mortality: An observational cohort study. Dautzenberg MJD, Wekesa AN, Gniadkowski M, Antoniadou A, Giamarellou H, Petrikkos GL, Skiada A, Brun-Buisson C, Bonten MJM, Derde LPG, the Mastering hOSpital Antimicrobial Resistance in Europe Work Package 3 Study Team.*Critical Care Medicine,* 2015;43:1170-1177 (doi: 10.1097/CCM.0000000000001028).
12. Molecular epidemiology of MRSA in 13 ICUs from eight European countries. Hetem DJ, Derde LP, Empel J, Mroczkowska A, Orczykowska-Kotyna M, Kozińska A, Hryniewicz W, Goossens H, Bonten MJ; MOSAR WP3 Study Group. *Journal of Antimicrobial Chemotherapy*, 2016; 71: 45–52 (doi: 10.1093/jac/dkv298).

* **Total citation** (Scopus):563
* **h-Index (Scopus):** 13

More details at <http://www.scopus.com/authid/detail.url?authorId=6603462581>

**Total citations (Scopus):** 489 citations by 458 documents (<http://www.scopus.com/authid/detail.url?authorId=6603462581>)

**h-Index (Scopus):** 12 (<http://www.scopus.com/authid/detail.url?authorId=6603462581>)

**Abstracts in international congresses:** 52

**Publications in Greek journals:** 12

**Abstracts in national congresses:** 67

**Books, book chapters and various editions**: 6 book chapters and 7 chapters in various editions

**International collaborations and research projects**

Collaborating scientist in the following International Research Project:

1. Severe *Streptococcus pyogenes* disease in Europe (Strep-EURO) <http://www.2020-horizon.com/STREP-EURO-Severe-streptococcus-pyogenes-disease-in-europe(STREP-EURO)-s40418.html>
2. Combating Antibiotics Resistant Pneumococci by Novel Strategies Based on *in vivo* and *in vitro* Host – Pathogen Interactions (CAREPNEUMO) <http://www.helmholtz-hzi.de/en/research/research_projects/view/projekt/projekt/carepneumo/>
3. Establishment of Quality Assurances for Detection of Highly Pathogenic Bacteria of Potential Bioterrorism Risk (EQADeBa) <http://www.rki.de/EN/Content/Prevention/ENHPB/EQADeBa-finalreport-2012.pdf?__blob=publicationFile>
4. Quality Assurance Exercises and Networking on the Detection of Highly Pathogenic Bacteria (QUANDHIP) <http://www.quandhip.info/Quandhip/EN/Home/Homepage_node.html>
5. Efficient response to highly dangerous and emerging pathogens at EU level (EMERGE) <http://www.emerge.rki.eu/Emerge/EN/Home/Homepage_node.html>

**National collaborations and research projects**

Collaborating scientist or scientific supervisor in the following National Research Project:

1. PENED 1999 – EPET II, 2000-2001. Data mining in the epidemiology of infections.
2. Pythagoras II, 2005-2006. Epidemiological investigation of anaerobic infections (scientific supervisor of the project).
3. EPIDPOLK, 2005-2008. Epidemiological investigation of multiresistant bacteria isolated in Cypriot Hospitals.
4. Archimedes II, 2012-2015. Nanoparticles in the diagnosis of bacterial infections.

**Teaching, tutorial and supervisor activities and experience**

* Teaching at the undergraduate courses “General Microbiology” and “Clinical Microbiology” and laboratory courses, third year students, Medical School, National and Kapodistrian University of Athens, 2004 – present.
* Teaching at the undergraduate courses “General Microbiology” and “Clinical Microbiology”, second year students, School of Dentistry, National and Kapodistrian University of Athens, 2004 – present.
* Teaching at the postgraduate course “Microbiology – Mycology” of the Postgraduate Master Program “Clinical Biochemistry – Molecular Diagnosis”, National and Kapodistrian University of Athens, 2008 – present.
* Teaching at the postgraduate course “Pharmaceutical Microbiology” of the Postgraduate Master Program “Industrial Pharmacy - Pharmaceutical Analysis”, National and Kapodistrian University of Athens, 2013 – present.
* Teaching at the postgraduate course “Microbiology and Public Health” of the Postgraduate Master Program “Applications of Biology in Medicine”, National and Kapodistrian University of Athens, 2016 – 2017.
* Teaching at the postgraduate course “Disaster Medicine” of the Postgraduate Master Program “International Medicine – Health Risk Management”, National and Kapodistrian University of Athens, 2016 – 2017.
* Supervisor of the postgraduate courses “General Principles of Molecular Techniques”, “General Principles of Bacteriology – Molecular methods in Bacteriology”, and “Molecular Bacteriology Laboratory” of the Postgraduate Master Program “Molecular Medical Biopathology - Microbiology”, National and Kapodistrian University of Athens, 2016 – 2017.
* Teaching at the postgraduate courses for residents of Medical Biopathology, Hellenic Society for Microbiology, 2006 – present.
* Member of the PhD thesis committee of eight PhD students (in three students as direct supervisor). Four students have successfully concluded their thesis whilst the remaining four are at various completion stages.

**Clinical and Diagnostic Experience**

* 2004 – Today: Scientific Supervisor, Bacteriology - Molecular Diagnostic Unit and Biosafety Level III Containment Laboratory, Biosafety and Biosecurity Officer, Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Greece.
* 2002 – 2004: Consultant Clinical Microbiologist, National Health System (NHS), Department of Microbiology, “Laikon” General Hospital, Athens, Greece.
* 1994 – 1999. Resident in Medical Biopathology, “Laikon” General Hospital, Athens, Greece.

**Brief presentation of the Bacteriology - Molecular Diagnostic Unit and the Biosafety Level III Containment Laboratory.**

1. The Unit applies molecular and conventional techniques for the diagnosis of the following pathogens: *Mycobacterium tuberculosis complex, Mycobacterium avium/intracellulare complex, Brucella spp. Chlamydophila pneumoniae/psittaci, Chlamydia trachomatis, Mycoplasma pneumoniae, Legionella pneumophila, Leptospira* spp., *Borrelia burgdorferi, Coxiella burnetii, Rickettsia* spp., *Bacillus anthracis, Yersinia pestis, Francisella tularensis, Burkholderia mallei, Burkholderia pseudomallei*.
2. It poses full biosafety level III facilities for diagnostic and research purposes. It is one of the three level III laboratories implemented in Athens during the 2004 Olympic Games. It currently provides 24/7 coverage for the Hellenic Centre for Disease Control and Prevention (KEELPNO, <http://www.keelpno.gr/en-us/home.aspx>) regarding bacterial agents of deliberate release.
3. The personnel have received training in the Biosafety III-IV laboratories of the Rare and Imported Pathogens Laboratory (formerly Special Pathogens Reference Unit), Public Health England, at Porton Down, Salisbury, UK.
4. It participates in the Working Groups of the European Union (Directorate General for Health and Consumers – DG SANCO) regarding diagnosis of highly pathogenic bacterial and viral agents, the respective multicenter research projects (EQADeBa, QUANDHIP) and the Pan-European annual exercises.